Image of a couple hugging with text that says "Välkommen till Oncopeptides, Innovationen für Patienten mit hämatologischen Erkrankungen"

Bringing hope through science

Oncopeptides is a global biotech company, founded in Sweden, focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is science driven and is committed to bringing innovation to patients with an unmet need and improving patient lives.

Sofia Heigis, CEO

Sofia Heigis appointed CEO of Oncopeptides AB

On August 7, 2023, Oncopeptides announced that the Board of Directors has appointed Sofia Heigis as Chief Executive Officer, CEO, of Oncopeptides and replaces Monica Shaw. These changes are effective immediately.

Read the press release on the global website

Multiple myeloma

Multiple myeloma is a cancer of the bone marrow that results in production of abnormal blood plasma cells. The disease is linked to substantial morbidity and mortality, and there is currently no cure. Patients being treated for multiple myeloma will experience symptom free periods, but they will relapse as the disease develops resistance to the treatment.

Image explaining the main characteristics of multiple myeloma

Image with statistics regaring multiple myeloma

The classic CRAB symptoms of multiple myeloma

Image showing the disease course of multiple myeloma

Image with information on relapsed and refractory multiple myeloma

Information on Extramedullary Diease (EMD)

Continuation of the information of Extramedullary Diease (EMD)

Image with information on what characteristics novel agents against multiple myeloma should have

Read the global press releases

Below is a link to our global press releases from Oncopeptides AB (publ). This link takes you to our global website.

To the global press releases

More about Pepaxti®

To the Pepaxti website

Fachinformation Pepaxti®